User menu

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

Bibliographic reference Kohli, M. ; Ferko, N. ; Martin, A. ; Franco, E. L. ; Jenkins, D. ; et. al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. In: The British journal of cancer, Vol. 96, no. 1, p. 143-150 (2007)
Permanent URL
  1. Bell S, Prev Med, 24, 610 (1999)
  2. Canfell K, Barnabas R, Patnick J, Beral V, The predicted effect of changes in cervical screening practice in the UK: results from a modelling study, 10.1038/sj.bjc.6602002
  3. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJLM, Franceschi S, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, 10.1016/s0140-6736(05)67069-9
  4. Clifford G. M., Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer, 10.1158/1055-9965.epi-04-0812
  5. Clifford G M, Smith J S, Aguado T, Franceschi S, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, 10.1038/sj.bjc.6601024
  6. Clifford G M, Smith J S, Plummer M, Muñoz N, Franceschi S, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, 10.1038/sj.bjc.6600688
  7. Cogliano Vincent, Baan Robert, Straif Kurt, Grosse Yann, Secretan Béatrice, Ghissassi Fatiha El, Carcinogenicity of human papillomaviruses, 10.1016/s1470-2045(05)70086-3
  8. Cuzick J., Szarewski A., Terry G., Hanby A., Maddox P., Anderson M., Steele S.J., Guillebaud J., Kocjean C., Human papillomavirus testing in primary cervical screening, 10.1016/s0140-6736(95)91086-7
  9. de Rijke J.M, van der Putten H.W.H.M, Lutgens L.C.H.W, Voogd A.C, Kruitwagen R.F.P.M, van Dijck J.A.A.M, Schouten L.J, Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986–1996, 10.1016/s0959-8049(02)00315-5
  10. Franco Eduardo L., Cuzick Jack, Hildesheim Allan, de Sanjosé Silvia, Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination, 10.1016/j.vaccine.2006.05.061
  11. Franco E. L., Rohan T. E., Villa L. L., Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer, 10.1093/jnci/91.6.506
  12. Franco Eduardo L., Villa Luisa L., Sobrinho João P., Prado José M., Rousseau Marie‐Claude, Désy Marie, Rohan Thomas E., Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer, 10.1086/315086
  13. Goldie SJ, J Natl Cancer Inst, 96, 604 (2004)
  14. Harper Diane M, Franco Eduardo L, Wheeler Cosette, Ferris Daron G, Jenkins David, Schuind Anne, Zahaf Toufik, Innis Bruce, Naud Paulo, De Carvalho Newton S, Roteli-Martins Cecilia M, Teixeira Julio, Blatter Mark M, Korn Abner P, Quint Wim, Dubin Gary, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, 10.1016/s0140-6736(04)17398-4
  15. Harper Diane M, Franco Eduardo L, Wheeler Cosette M, Moscicki Anna-Barbara, Romanowski Barbara, Roteli-Martins Cecilia M, Jenkins David, Schuind Anne, Costa Clemens Sue Ann, Dubin Gary, Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, 10.1016/s0140-6736(06)68439-0
  16. Ho Gloria Y.F., Bierman Robert, Beardsley Leah, Chang Chee J., Burk Robert D., Natural History of Cervicovaginal Papillomavirus Infection in Young Women, 10.1056/nejm199802123380703
  17. Holowaty P., Miller A. B., Rohan T., To T., Natural History of Dysplasia of the Uterine Cervix, 10.1093/jnci/91.3.252
  18. Hopman E. H., Kenemans P., Helmerhorst Th. J. M., Positive Predictive Rate of Colposcopic Examination of the Cervix Uteri : An Overview of Literature, 10.1097/00006254-199802000-00021
  19. Jenkins David, Sherlaw‐Johnson Chris, Gallivan Steve, Can papilloma virus testing be used to improve cervical cancer screening?, 10.1002/(sici)1097-0215(19960315)65:6<768::aid-ijc10>;2-9
  20. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N, Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis, 10.3310/hta8200
  21. Koutsky Laura A., Ault Kevin A., Wheeler Cosette M., Brown Darron R., Barr Eliav, Alvarez Frances B., Chiacchierini Lisa M., Jansen Kathrin U., A Controlled Trial of a Human Papillomavirus Type 16 Vaccine, 10.1056/nejmoa020586
  22. Kulasingam Shalini L., Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs, 10.1001/jama.290.6.781
  23. Melnikov J, Obstet Gynecol, 92, 727 (1998)
  24. Mitchell M, Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis, 10.1016/s0029-7844(98)00006-4
  25. Molano M., Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study, 10.1093/aje/kwg171
  26. Moscicki Anna-Barbara, Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young Females, 10.1001/jama.285.23.2995
  27. Muñoz Nubia, Bosch F. Xavier, Castellsagué Xavier, Díaz Mireia, de Sanjose Silvia, Hammouda Doudja, Shah Keerti V., Meijer Chris J.L.M., Against which human papillomavirus types shall we vaccinate and screen? the international perspective : HPV Types for Vaccines and Screening Tests, 10.1002/ijc.20244
  28. Peto J, Br J Cancer, 91, 942 (2004b)
  29. Peto Julian, Gilham Clare, Fletcher Olivia, Matthews Fiona E, The cervical cancer epidemic that screening has prevented in the UK, 10.1016/s0140-6736(04)16674-9
  30. Schlecht N. F., Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia, 10.1093/jnci/djg037
  31. Sherlaw-Johnson C, Gallivan S, Jenkins D, Royston G., Withdrawing low risk women from cervical screening programmes: mathematical modelling study   Commentary: trials versus models in appraising screening programmes, 10.1136/bmj.318.7180.356
  32. Sherlaw-Johnson C, J Clin Pathol, 47, 430 (1994)
  33. Sherlaw-Johnson C, Philips Z, An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme, 10.1038/sj.bjc.6601884
  34. Taira Al V., Neukermans Christopher P., Sanders Gillian D., Evaluating Human Papillomavirus Vaccination Programs, 10.3201/eid1011.040222
  35. Villa Luisa L, Costa Ronaldo LR, Petta Carlos A, Andrade Rosires P, Ault Kevin A, Giuliano Anna R, Wheeler Cosette M, Koutsky Laura A, Malm Christian, Lehtinen Matti, Skjeldestad Finn Egil, Olsson Sven-Eric, Steinwall Margareta, Brown Darron R, Kurman Robert J, Ronnett Brigitte M, Stoler Mark H, Ferenczy Alex, Harper Diane M, Tamms Gretchen M, Yu Jimmy, Lupinacci Lisa, Railkar Radha, Taddeo Frank J, Jansen Kathrin U, Esser Mark T, Sings Heather L, Saah Alfred J, Barr Eliav, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, 10.1016/s1470-2045(05)70101-7
  36. Wallace L A, Determinants of universal adolescent hepatitis B vaccine uptake, 10.1136/adc.2003.043687